Jeffrey Calcagno, M.D.

Jeffrey Calcagno, M.D.

Executive Vice President and Chief Business OfficeratVir Biotechnology· In the 2023 proxy

Pay in FY2023Vir Biotechnology stock -60.3% the same year

Jeffrey Calcagno, M.D. was paid $4.5M in FY2023 (Dec). Vir Biotechnology stock fell 60.3% that year.

Pay$100 in the stock at the end of FY22 → $40
Pay is from the Summary Compensation Table of each Vir Biotechnology proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Vir BiotechnologyPublic company · 3 yr
    • Executive Vice President and Chief Business Officer2023 – Present · 3 yrStock in role -52%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?